Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0MRJEG)
| ADC Name |
REGN5093-M114
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
REGN5093-M114
Click to Show/Hide
|
|||||
| Organization |
Regeneron Pharmaceuticals (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
3.2
|
|||||
| Structure |
|
|||||
| Antibody Name |
REGN5093
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Maytansine derivative M24
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
SC-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible: Advanced NSCLC (no standard options), ECOG 0-1, MET overexpression (fresh/archival biopsy ≤6 months old), measurable lesion (s) (expansion), adequate organ function. Excluded: Recent systemic therapy (<2 weeks/5 half-lives), unresolved toxicities (>grade 1), active CNS disease, uncontrolled infections (HIV/HBV/HCV), or concurrent malignancy. Prior irradiation requires documented progression in irradiated lesions.
Click to Show/Hide
|
||||
| Administration Dosage |
Cohorts A and B: REGN5093-M114 monotherapy. Cohort C: REGN5093-M114+cemiplimab combination.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04982224 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2 Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Patients With MET Overexpressing Advanced Cancer | ||||
| Primary Endpoint |
Phase 1 dose escalation will assess safety through DLTs (28-day window), TEAEs, SAEs, treatment discontinuations, deaths, and CTCAE grade 3+ lab abnormalities over ~2 years. Pharmacokinetics include serum concentrations of REGN5093-M114 (total/conjugated), plasma M24 levels, and cemiplimab concentrations (Cohort C). Phase 2 expands ORR evaluation.
|
||||
| Other Endpoint |
Efficacy/Safety (both phases): ORR, TEAEs, SAEs, treatment-limiting toxicities, lab abnormalities, PK of REGN5093-M114/M24/cemiplimab (Cohort C), and ADA incidence/titer against cemiplimab/REGN5093-M114. Tumor response endpoints (DOR, DCR, TTR, PFS, OS) are tracked over 2 years.
|
||||
References